Screener
ArriVent BioPharma, Inc. AVBP Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $62,103 | $45,540 |
| Short-term investments | 264,277 | 267,281 |
| Prepaid expenses and other current assets | 22,320 | 20,076 |
| Total current assets | 348,700 | 332,897 |
| Right of use assets – operating leases | 370 | 13 |
| Deferred offering costs | 69 | 69 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s cash & equivalents?
- ArriVent BioPharma, Inc. (AVBP) reported cash & equivalents of $62.1M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s cash & equivalents changed year-over-year?
- ArriVent BioPharma, Inc.'s cash & equivalents increased by 24.5% year-over-year, from $49.87M to $62.1M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s cash & equivalents?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s cash & equivalents has grown at a -45.0% compound annual growth rate (CAGR), from $150.39M to $45.54M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about ArriVent BioPharma, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude